Correct!
5. Both 1 and 2

Life-threatening CMV pneumonia may develop in the immunocompromised patient with the incidence varying based on the type of transplant received and level of immunosuppression. Those most at risk include bone-marrow transplant recipients and recipients of lung transplants (5). Fatal CMV pneumonia is much less common in patients who have received solid organ transplants than in those who have received marrow transplants. The mortality rate among bone marrow transplant recipients with CMV pneumonia was approximately 85% prior to the introduction of ganciclovir and CMV-specific immune globulin, decreasing the mortality rate to 15-75%.

References

1. Gotway MB, Reddy GP, Webb WR, Elicker BM, Leung JW. High-resolution CT of the lung: patterns of disease and differential diagnoses. Radiol Clin North Am. 2005;43(3):513-42.
2. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005; 352:373-9.
3. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286-91.
4. Chi DC, Brogan F, Turenne I, Zelonis S, Schwartz L, Saif MW. Gemcitabine-induced pulmonary toxicity. Anticancer Res. 2012;32(9):4147-9.
5. Reed EC, Bowden RA, Dandliker PS. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patient with bone marrow transplants. Ann Intern Med. 1988:109(10):783-8.

Home/Critical Care